Funding Agency:

National Institutes of Health, National Institute of Neurological Disorders and Stroke (Grant No. P01-NS040923)

Total Project Period:

3/1/08 - 2/28/13

Total Project Award:

$6,240,198

Principal Investigator:

Ian F. Pollack, MD

Co-Investigators:

William F. Chambers, PhD (University of Pittsburgh Cancer Institute); Neal A. DeLuca, PhD, (Department of Molecular Genetics and Biochemistry), Elaine Elder, ScD (Department of Pathology); John C. Flickinger, MD (Department of Radiation Oncology); Joseph C. Glorioso, PhD (Department of Molecular Genetics and Biochemistry); Ronald Hamilton, MD (Department of Pathology); Glenn T. Gobbel, PhD; John S. Lazo, PhD (Department of Pharmacology); Frank Lieberman, MD (Department of Neurology); Clifford Schold, MD (Department of Neurology); Michael T. Lotze, MD, (Department of Surgery); L. Dade Lunsford, MD, Ajay Niranjan, MD, Douglas Kondziolka, MD, Hideho Okada, MD, PhD, Simon Watkins, PhD (Department of Cell Biology and Physiology); Theresa Whiteside, PhD (Department of Pathology and Otolaryngology)

Project Summary:

The unifying hypothesis of this program project is that novel therapeutic strategies that take into account the unique features of malignant brain tumors will induce tumor regression, and potentiate conventional therapies. Each project is translationally oriented, with a common goal of addressing fundamental biological issues relevant to tumor growth and evaluating innovative clinical therapies.